With Sonic, PIQ was set to get royalty revenue of about $40 USD per test.
With the new strategy PIQ set to get revenue $400 USD per test, but with increased cost, maybe $100 per test.
Not to understate the importance of early diagnosis of endometriosis of Eso cancer, but the clinical roadshow is suggesting Promarker-D at least annually for diabetics!
Ann: PromarkerD outperforms conventional tests--results published, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $62.19M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.0¢ | 36.0¢ | $53.71K | 143.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 491 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 39195 | 2 |
View Market Depth
| Last trade - 15.55pm 07/08/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |